Objective. Skin damage caused by chronic venous disease (CVD) is associated with severe microangiopathic changes in the skin. The aim was to determine whether patients in various CEAP clinical stages of CVD have elevated plasma levels of VEGF compared to controls and whether this correlates with the symptoms. Methods. One hundred and eight patients with CVD attending the vascular clinic were included and assigned to the appropriate CEAP clinical stage. Thirty healthy control subjects were also included. Patients and controls were studied after resting supine for 10 min. Blood samples were taken from a dorsal foot vein. Assay of VEGF was performed with an enzymelinked immunosorbent assay. Volunteers' symptoms were recorded using a visual analogue scale (VAS) for heaviness, cramps, paraesthesiae and swelling. Results. Plasma levels of VEGF were: control ðn30Þ median VEGF 56 pg/ml (inter-quartile range IQR 38 -85), CEAP C2 (varicose veins) 86 (39 -133), C5 (healed ulcer) 88 (67-135). Median difference: control vs. C5 33 (95% confidence interval (CI) 8 -61). Median differences were calculated using the Wilcoxon method. VEGF level in patients with VAS swelling score ¼ 0:54 pg/ml (IQR 31 -104). VEGF level in patients with VAS swelling score . 0:85 pg/ml . Difference between medians: 20 ng/ml, 95% CI for the median difference: (5-44). No differences were observed for symptoms of heaviness, cramps or paraesthesiae.
Introduction
Venous valvular incompetence of lower limb veins leads to chronic venous disease (CVD). This may result in symptoms varying from uncomplicated varicose veins to oedema, liposclerotic skin changes and ulceration. These symptoms occur in between 3 1 and 11% of the population. 2 Venous disease of the legs affects up to 9% of the total population, a risk that increases with age and occurs with equal prevalence in men and women, according to a carefully conducted epidemiological study. 3 Several theories concerning the pathogenesis of venous ulcers have been proposed. The most recent one suggests that leucocytes, which accumulate in the microcirculation during venous hypertension, become activated releasing toxic metabolites, proteolytic enzymes and free radicals. 4 Several studies implicate inappropriate neutrophil activation as the most likely mechanism of tissue damage in this disease. 5, 6 The full sequence of events resulting in venous ulceration still remains unclear.
Skin damage caused by chronic venous insufficiency is associated with severe microangiopathic changes in the skin. This was first recognized histologically by Burnand et al. 7 Normal skin has occasional capillaries on histologic sections, and the number of capillaries does not increase among patients with varicose veins. Microscopic examination of the capillaries has been used to study the microcirculation of the skin in the presence of venous disease. 8 The microangiopathy in CVD is characterised by the presence of enlarged, dilated, coiled and ramified capillaries, which are surrounded by an enlarged pericapillary spaces (halos) 9 and reduced capillary numbers, microvascular thrombosis, obliterations and increased permeability of microlymphatics 10 depending on the severity of the CVD.
The proliferation of the capillary endothelium has not been fully explained, although production of vascular endothelial growth factor (VEGF) in the epidermis has been demonstrated. 11 A possible explanation of the microangiopathic changes is that VEGF reaches the main capillaries in the underlying papillary dermis and causes them to proliferate. Many growth factors have been identified that might be responsible for the angiogenic response in CVD. 12, 13 The aim of our study was to measure the basal plasma VEGF levels among control subjects and different CEAP (Clinico Etiologic Anatomic Pathologic) 14 stages of patients with chronic venous. We also wished to explore the relationship between symptoms attributable to venous disease and VEGF.
Materials and Methods
Patients considered for the entry into the study were those of attending The Middlesex Hospital Outpatient for the management of venous disease. Those suitable for the inclusion in the study were canvassed by a letter of explanation indicating the nature of the study. Patients with CEAP clinical class C2 (varicose veins), C3 (oedema), C4 (skin changes) and C5 (healed ulcer) were considered. Thirty normal healthy volunteers acted as control subjects (CO). This group comprised of the members of the department of Surgery and Haematology, patients treated for unrelated conditions at The London Foot Hospital and normal healthy volunteers from the general public. They had no symptoms or signs of arterial or venous disease of the lower limb.
The inclusion criteria for the study were patients of C2 -C5 stage of CEAP clinical stage of CVD from either sex, age above 18 years old and of any race. Exclusion criteria have been shown in Table 1 .
Patients and volunteers fulfilling the entry criteria and giving informed written consent were studied further. Approval for the study was obtained from UCL Medical School Committee for medical ethics. Thirty normal volunteers (13M:17F, median age 53 years, range 47-56 years) and 108 patients (47M:61F, median age 53 years, range 44-61 years) with CVD were studied.
All patients were assessed clinically by a vascular surgeon skilled in the management of venous diseases to determine the clinical grade of the CEAP classification. A medical history was taken and clinical examination was performed. This included a systemic as well as venous examination. All patients had a full blood count, serum urea and electrolytes and liver function tests. Patients included in the study underwent standard vascular laboratory investigation, as part of their routine management for venous disease, including duplex ultrasonography and measurement of photoplethysmography venous refilling times. The numbers of patients and controls studied and their age and sex distribution including their duplex findings in various groups of CEAP are summarised in Table 2 .
Procedure
The study was conducted in an environmental chamber at 22 8C. All the patients and control subjects were acclimatised for 10-20 min, whilst lying supine before the start of the experimental protocol to minimize venous pressure in the leg. A 23-gauge canula (Venisystemse Butterfly w , Abbott, Ireland) was placed in the distal long saphenous vein or dorsal foot vein of the most affected leg. Blood was collected into EDTA tubes and plasma was separated by centrifugation. Samples were frozen at 2 84 8C before analysis. Assay of VEGF 165 protein was performed by commercially available ELISA kits manufactured by R&D Systems Europe, UK, once all samples were collected. The symptoms of venous insufficiency (pain, cramps, heaviness, paraesthesiae and swelling) were assessed by the investigator with the patient using a visual analogue scale (VAS of 10 cm). Scale was marked 0 -10 cm, severe symptoms were graded 10, where absence of symptoms were marked as 0.
Patients were asked to place a vertical mark on a 10 cm horizontal line marked with 'no symptoms' at one end and 'maximum symptoms' at the other end.
This was only done for the patients not for the controls as the controls were selected on the basis of absence of symptoms and visible varicose veins (CO).
Analysis of data
The difference between medians and 95% CI were calculated using the Wilcoxon method. All results are described as median (interquartile range, IQR).
Results
One hundred and thirty-two patients were screened for the study and 24 patients were excluded on the basis of the exclusion criteria mentioned in Table 1 .
The subjects in each of the groups were of similar age and sex distribution. The number of patients with the superficial and the deep venous incompetence among the study groups and the demographic details on subjects included are shown in Table 2 .
The median plasma VEGF 165 levels (pg/ml) for patients were higher (85 pg/ml) than controls (56 pg/ml) and has been shown in Table 3 . The median value for our control subjects (56 pg/ml lying supine) is very close to the data provided by the manufacturers of the ELISA kit (R&D Systems) who quote a median value of 62 pg/ml for control subjects. Fig. 1 shows that plasma levels of VEGF were higher among various groups of patients than controls, but statistical significance was only reached in the C5 group compared to controls. This was probably due to the wide scatter of data. The levels of VEGF were approximately 60% higher for the patient groups than for the control group.
The association of symptoms with plasma VEGF has been investigated in the patient group and the results shown in Table 4 . The symptom data was separated into upper and lower halves for each symptom and the median VAS score calculated for each group. Fourth column of Table 4 , shows that this has resulted in groups of patients with substantially different symptoms. The fifth column shows the corresponding plasma VEGF levels. For the symptoms of heaviness, cramps and paraesthesiae no statistically significant different difference was found between patients with few symptoms and those with most symptoms. However, for the symptom of oedema the symptomatic patients had significantly elevated plasma VEGF levels. This outcome may simply have occurred by chance. To investigate the relationship between symptoms and VEGF levels, Pearson's correlation coefficient ðrÞ has also been calculated for symptoms measured by the VAS and the corresponding plasma VEGF levels. The result is shown in the sixth column of Table 4 . The value of this is universally low, confirming the lack of correlation between symptoms and biological markers. 
Discussion
Previous studies on VEGF have been reported on limited numbers of patients. In this investigation, a substantial number of patients (108) have been investigated and compared to 30 control subjects. This greatly increased patient cohort ensured that our measurements are reliable when considering that, in venous disease, relatively small changes of inflammatory mediator levels have been sought. We took considerable care to exclude any patient from the study where any disease process or medication may have interfered with the measurements. A further factor which may confound studies of this type is the tendency for age differences to arise between patients with varicose veins (C2) and those with skin changes and healed ulcers (C4, C5). In this cohort of patients, the age of the control and patients groups is very similar.
In our study, there was a trend towards higher levels of VEGF in all patients groups than in controls, but this only achieved statistical significance in the C5 patients, due to the large scatter of the data. The levels of VEGF among patients are similar to those with skin changes (C4, C5) as those without skin changes (C2, C3). While it is thought that VEGF may contribute to the capillary proliferation seen in advanced CVD, 15 it is not clear whether it is hypoxia induced or directly related to capillary proliferation or both. Therefore, 'cause and effect' could not be established with this study. It is also known that the capillary density is reduced in advanced forms of CVD (C4, C5), although capillary convolution and proliferation are prominent features. 16, 17 Cutaneous capillary proliferation may either be in response to hypoxia via VEGF pathway or some other unknown mechanisms. The trend towards elevated VEGF levels seen in the C2 and C3 patients is unlikely to reflect capillary proliferation in the skin, since this is not normally a feature of uncomplicated venous disease. It remains to be explored whether this raised VEGF in C2 CVD is due to increased capillary density seen in fluorescein microscopy, or in C3 CVD due to oedema where VEGF acts as permeability factor or in C4, C5 CVD as part of reparative process as evidenced by capillary proliferation. In fact, the explanation for this observation remains unclear, while the origin of VEGF measured in patients from the C5 group is also unknown. If it is epidermal origin then it may contribute to skin damage via VEGF-NO pathway or it may simply be a response to local reparative and increased angiogenic process or act simply as vascular permeability factor. In our previous study, similarly increased total plasma NO in all disease groups had been shown, which did reach a statistically significant level. 18 Correlation of symptoms with VEGF was also investigated in this study. This was done because it has been observed that there is a poor correlation between the severity of physiological abnormality of the venous system and the resulting symptoms. We observed higher plasma levels of VEGF in patients with the higher range of the 'oedema' symptom. Further investigation of the correlation between symptoms and plasma VEGF levels showed that there was no consistent relationship. The data from this study show that all groups of patients had similar elevations in plasma VEGF level compared with controls. This may reflect the fact that this growth factor is induced in patients with venous disease to repair tissue damage caused by venous hypertension. However, measurement of plasma levels may not reliably reflect the actual tissue levels expressed in the region of tissue repair. It is unlikely that VEGF as reflected by these plasma levels is an important factor in explaining the differences between C3 and C4 patients.
Epidermally derived VEGF is likely to be a factor in the angiogenesis of lipodermatosclerosis. This increased expression of VEGF is seen even before any skin changes develop. We found increased serum levels of VEGF in our study with patients with venous disease. In our study, the changes in serum levels were actually more prominent among the group with C3 disease. Studies that measure the expression of VEGF mRNA levels might more conclusively prove the actual site of origin of the protein.
Conclusions
The was a trend to increased plasma VEGF levels in all groups of patients, but only patients with healed ulcers (C5) showed statistically raised VEGF levels. This may reflect the fact that this growth factor is induced in patients with venous disease to repair tissue damage caused by CVD. No consistent relationship was found between symptoms recorded by VAS and plasma levels of VEGF.
